Takeda and Sunovion announced new data on the short and long-term efficacy, safety, and tolerability of lurasidone (Latuda; Sunovion) in adults with schizophrenia.
Novartis announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) has unanimously voted in support of the approval of AIN457 (secukinumab) for the treatment of moderate to severe plaque psoriasis.
Genzyme announced that the Food and Drug Administration (FDA) has approved the inclusion of clinical data from the TOWER and TOPIC studies of Aubagio (teriflunomide).
Auxilium announced that the Food and Drug Administration (FDA) has approved Xiaflex (collagenase clostridium histolyticum) for the treatment of up to 2 Dupuytren's contracture joints in the same hand during a single treatment visit.
Boehringer Ingelheim announced that Ofev (nintedanib) capsules are now available for the treatment of idiopathic pulmonary fibrosis (IPF).